Skip to main content

Table 3 Patterns of disease progression and subsequent outcomes

From: Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab

Characteristics n = 90
PD 57 (63)
 RECIST 51 (89)
 Clinical 5 (9)
 Both 1 (2)
Patients with new organ sites at time of RECIST PD 23 (44)
New organ sites at time of RECIST PD
 Brain 8 (35)
 Bones 1 (4)
 Liver 4 (17)
 Soft tissue 4 (17)
 Pleural 1 (4)
 Local 4 (17)
 Adrenal 3 (13)
Management after PD
 Subsequent systemic treatment 28 (49)
 Hospice 23 (40)
 Died 3 (5)
Subsequent therapies in PD group after nivolumab discontinued
 Cabozantinib 6 (21)
 Axitinib 14 (50)
 Everolimus 1 (4)
 Temsirolimus 3 (11)
 Sunitinib 2 (7)
 Others* 2 (7)
  1. *One patient was enrolled in a clinical trial investigating an experimental drug in combination with Atezolizumab. A second patient was enrolled in a clinical trial and randomized to receive tivozanib